Navigation Links
Penn Dental Medicine, CHOP Team Show HIV/AIDS Drugs Interfere with Brain's 'Insulation'
Date:1/18/2016

PHILADELPHIA, Jan. 18 2016 /PRNewswire/ -- Antiretroviral therapies (ART) have enabled people with HIV/AIDS to live much longer lives, essentially transforming the disease into a chronic condition. Yet concerns for these patients remain. Up to half of people with HIV on these drug regimens have some sort of cognitive impairment, such as memory loss or problems with executive functioning, despite the virus being almost undetectable in their bodies.

In a new study, researchers from Penn Dental Medicine and The Children's Hospital of Philadelphia teamed up to investigate the underlying reasons for these impairments. They found that commonly used antiretroviral medications (protease inhibitors Ritonavir and Lopinavir) disrupted the differentiation of oligodendrocytes, crucial brain cells that manufacture myelin, the fatty material that serves to insulate neurons, helping them transmit signals in the brain fast and efficiently.

This disruption, the researchers said, may be responsible for some of the cognitive problems that HIV patients experience, and point to a need for rethinking how HIV drugs are designed and prescribed, particularly for children on ART, in whom myelin is still forming at high rates.

"Pharmaceutical companies have done an amazing job developing drugs to make HIV patients live longer, but we're not done," said Kelly L. Jordan-Sciutto, professor and chair of Penn Dental Medicine's Department of Pathology, who co-led the research with Judith B. Grinspan, a research scientist at CHOP and professor of neurology at Penn's Perelman School of Medicine. "The message we want to get out there is that we want to make these patients' lives better while they are on ART."

The research was published this November in the Journal of Neuropathology and Experimental Neurology.

The researchers have yet to determine a mechanism by which myelin protein levels are altered with ART, but are investigating a number of avenues. They are also evaluating how different HIV medications can affect oligodendrocyte and myelin formation, as the recommended drug cocktails frequently change.

The implications of these findings may be particularly important for pediatric patients, some of whom may have been on ART from birth. Since HIV-infected children exhibit higher rates of neurocognitive disorders such as seizures, depression, and ADHD, the researchers stress that a revised look at treatments for pediatric patients may be warranted, or an additional therapy to prevent the white matter loss in both adults and children could be developed to go hand in hand with the ART.

Contact:
Beth Adams
215-573-8224
adamsnb@upenn.edu


'/>"/>
SOURCE Penn Dental Medicine
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference
2. Heska Corporation to Present at the Stifel Dental & Veterinary Conference
3. Stanley Bergman Delivers Commencement Address At Stony Brook School Of Dental Medicine
4. Umbie DentalCare - Multiple Opportunities One Solutions
5. GRW bearing lubrication tests yield maximum wear life for medical and dental instruments
6. SmileBest Dental & Orthodontics Opens Their First Office in Hurst, Texas
7. Henry Schein Dental And American Dental Hygienists Association Host "Dream Center" To Mark 100th Anniversary Of Profession
8. TopProdeals.com Rises to Top as Discount Dental Supply Leader
9. Global Dental Restorative Supplies Industry
10. Global Dental Orthodontic Supplies Industry
11. Henry Schein Chairman Of The Board & CEO Receives Centennial Recognition Award For Extraordinary Commitment To The National Dental Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease Control ... of October . PhysicianOne Urgent Care is helping communities across ... NY , by offering no-cost* flu shots through the end of ... by certain health insurance regulations. ... best time to get a flu shot is by the end of ...
(Date:10/2/2017)... 2, 2017  AllianceRx Walgreens Prime, the combined central ... and pharmacy benefit manager Prime Therapeutics LLC (Prime), today ... included the unveiling of new signage at its headquarters ... as at a few other company-owned facilities across the ... patients, some of whom will begin to see the ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... D.C., for the 49th Congress of the International Society of Paediatric Oncology ... the Center for Cancer and Blood Disorders at Children’s National, and Stephen ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
Breaking Medicine News(10 mins):